Literature DB >> 9835531

Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.

Z Li1, T Deguchi, M Yasuda, T Kawamura, E Kanematsu, Y Nishino, S Ishihara, Y Kawada.   

Abstract

We examined 22 clinical isolates of Staphylococcus epidermidis to analyze the association of alterations in GyrA and ParC with fluoroquinolone resistance. The simultaneous presence of GyrA and ParC alterations was associated with a high level of fluoroquinolone resistance in the clinical isolates of S. epidermidis.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9835531      PMCID： PMC106039     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  S Sreedharan; L R Peterson; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

2.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

4.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.

Authors:  E Kanematsu; T Deguchi; M Yasuda; T Kawamura; Y Nishino; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

8.  DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae.

Authors:  T Deguchi; M Yasuda; M Asano; K Tada; H Iwata; H Komeda; T Ezaki; I Saito; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins.

Authors:  E E Margerrison; R Hopewell; L M Fisher
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490

10.  Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.

Authors:  L Ferrero; B Cameron; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191
View more
  18 in total

1.  First characterization of fluoroquinolone resistance in Streptococcus suis.

Authors:  Jose Antonio Escudero; Alvaro San Millan; Ana Catalan; Adela G de la Campa; Estefania Rivero; Gema Lopez; Lucas Dominguez; Miguel Angel Moreno; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  ACS Chem Biol       Date:  2013-09-30       Impact factor: 5.100

3.  In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.

Authors:  H J Linde; M Schmidt; E Fuchs; U Reischl; H H Niller; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Benjamin H Williamson; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  Biochemistry       Date:  2015-01-23       Impact factor: 3.162

5.  Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.

Authors:  D T Dubin; J E Fitzgibbon; M D Nahvi; J F John
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.

Authors:  H Oh; N El Amin; T Davies; P C Appelbaum; C Edlund
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Oocytes can efficiently repair DNA double-strand breaks to restore genetic integrity and protect offspring health.

Authors:  Jessica M Stringer; Amy Winship; Nadeen Zerafa; Matthew Wakefield; Karla Hutt
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-07       Impact factor: 11.205

8.  Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  Wolfgang Haas; Chris M Pillar; Christine K Hesje; Christine M Sanfilippo; Timothy W Morris
Journal:  J Antimicrob Chemother       Date:  2010-04-30       Impact factor: 5.790

9.  Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.

Authors:  Katie J Aldred; Tim R Blower; Robert J Kerns; James M Berger; Neil Osheroff
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-20       Impact factor: 11.205

10.  Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.

Authors:  M Yamada; J Yoshida; S Hatou; T Yoshida; Y Minagawa
Journal:  Br J Ophthalmol       Date:  2008-05-06       Impact factor: 4.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.